EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug: Midazolam

Masao Togao iD, Koji Kawakami, Jun Otsuka, Gaku Wagai, Yuki Ohta-Takada, Shoichi Kado

Biopharmaceutics & Drug Disposition · 2020-07 · 41 (7) · 275-282

DOI: 10.1002/bdd.2244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 20.07.2020. Verfasst von Masao Togao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Safety Research Department, Yakult Central Institute, Kunitachi-shi, Tokyo, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The link between drug‐metabolizing enzymes and gut microbiota is well established. In particular, hepatic cytochrome P450 (CYP) 3A activities are presumed to be affected by gut microbiota. However, there is no direct evidence that the gut microbiota affects CYP3A metabolism or the clearance of clinically relevant drugs in vivo. Our purpose was to evaluate the effects of gut microbiota on in vitro and in vivo drug metabolism and on the clearance of midazolam, which is a standard CYP3A metabolized drug. Hepatic Cyp3a activity and in vitro midazolam hydroxylase activity were compared using specific pathogen‐free (SPF) and germ‐free (GF) mice. In a pharmacokinetics (PK) study, SPF and GF mice were intraperitoneally injected with 60 mg/kg of midazolam, and plasma and tissue concentrations were measured. Hepatic Cyp3a activity and midazolam hydroxylase activity were significantly lower in GF mice than in SPF mice. Notably, in the PK study, the area under the plasma concentration–time curve from time zero to infinity and the elimination half‐life were approximately four‐fold higher in GF mice compared with SPF mice. Furthermore, the concentration of midazolam in the brain 180 min after administration was about 14‐fold higher in GF mice compared with SPF mice. Together, our results demonstrated that the gut microbiota altered the metabolic ability of Cyp3a and the tissue accumulation of midazolam.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeAnimalsArea Under CurveBrainCytochrome P-450 CYP3AHalf-LifeHumansHypnotics and SedativesLiverMaleMiceMice, Inbred BALB CMice, Inbred ICRMidazolamTissue DistributionMembrane Proteins

Stichwörter der Autor:innen

CYP3Agerm-freegut microbiotamidazolampharmacokinetics

Substanzen

Cytochrome P-450 CYP3AHypnotics and SedativesMidazolamCyp3a11 protein, mouseMembrane Proteins

Autor:innen und Institutionen

  • Safety Research Department, Yakult Central Institute, Kunitachi-shi, Tokyo, Japan.

ORCID-Profile: Masao Togao

Zitieren

APA

Togao, M., Kawakami, K., Otsuka, J., Wagai, G., Ohta-Takada, Y., & Kado, S. (2020). Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug: Midazolam. Biopharmaceutics & Drug Disposition, 41(7), 275-282. https://doi.org/10.1002/bdd.2244

Vancouver

Togao M, Kawakami K, Otsuka J, Wagai G, Ohta-Takada Y, Kado S. Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug: Midazolam. Biopharmaceutics & Drug Disposition. 2020;41(7):275-282. doi:10.1002/bdd.2244

BibTeX
@article{Togao2020,
  author = {Togao, Masao and Kawakami, Koji and Otsuka, Jun and Wagai, Gaku and Ohta-Takada, Yuki and Kado, Shoichi},
  title = {Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug: Midazolam},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2020},
  volume = {41},
  number = {7},
  pages = {275--282},
  doi = {10.1002/bdd.2244}
}
Kostenlos starten →